{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T10:58:34Z","timestamp":1775386714911,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09770-6","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T10:13:51Z","timestamp":1775384031000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of ravulizumab in anti-acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"74","author":[{"given":"Haneen","family":"Sabet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrar","family":"AbuHamdia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esraa Y.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina Essam","family":"Abo-elnour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sultan Mohammed","family":"Alanazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud G. A.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Negida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"issue":"3","key":"9770_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/14712598.2023.2185131","volume":"23","author":"F Vanoli","year":"2023","unstructured":"Vanoli F, Mantegazza R. Ravulizumab for the treatment of myasthenia gravis. Expert Opin Biol Ther. 2023;23(3):235\u201341.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"9770_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","volume":"15","author":"M Oray","year":"2016","unstructured":"Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457\u201365.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"9770_CR3","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1097\/MJT.0000000000001454","volume":"28","author":"P Manu","year":"2021","unstructured":"Manu P, Rogozea LM, Roman-Filip C. Pharmacological management of myasthenia gravis: a century of expert opinions in Cecil textbook of medicine. Am J Ther. 2021;28(6):e631-7.","journal-title":"Am J Ther"},{"key":"9770_CR4","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.2147\/NDT.S374694","volume":"19","author":"T Vu","year":"2023","unstructured":"Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF. Ravulizumab in myasthenia gravis: a review of the current evidence. Neuropsychiatr Dis Treat. 2023;19:2639\u201355.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"9770_CR5","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, F\u00fcreder W, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 2019;133(6):530\u20139.","journal-title":"Blood"},{"issue":"26","key":"9770_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570\u201381.","journal-title":"N Engl J Med"},{"issue":"12","key":"9770_CR7","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard","year":"2017","unstructured":"Howard JF, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386.","journal-title":"Lancet Neurol"},{"issue":"5","key":"9770_CR8","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.","journal-title":"NEJM Evid."},{"issue":"5","key":"9770_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"issue":"5","key":"9770_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.","journal-title":"NEJM Evid"},{"issue":"4","key":"9770_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","volume":"96","author":"N Huntemann","year":"2025","unstructured":"Huntemann N, Gerischer L, Herdick M, Nelke C, Stascheit F, Hoffmann S, et al. C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis. J Neurol Neurosurg Psychiatry. 2025;96(4):310\u201321.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9770_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1378080","volume":"15","author":"N Katyal","year":"2024","unstructured":"Katyal N, Govindarajan R, Goyal N, Muley S, Muppidi S. Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Front Neurol. 2024;15:1378080.","journal-title":"Front Neurol"},{"issue":"1","key":"9770_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200331","volume":"12","author":"F Stascheit","year":"2025","unstructured":"Stascheit F, Sousa CDFD, Aigner A, Behrens M, Keller CW, Klotz L, et al. Ravulizumab and efgartigimod in myasthenia gravis: a real-world study. Neurol Neuroimmunol Neuroinflamm. 2025;12(1):e200331.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"9770_CR14","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/acn3.52051","volume":"11","author":"D Tokuyasu","year":"2024","unstructured":"Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, et al. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. Ann Clin Transl Neurol. 2024;11(5):1338\u201346.","journal-title":"Ann Clin Transl Neurol"},{"issue":"4","key":"9770_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/brainsci15040350","volume":"15","author":"C V\u00eelciu","year":"2025","unstructured":"V\u00eelciu C, Mihalache OA, Istrate BM, Marian MA, Dr\u0103ghici MR, Petrescu DM, et al. Real-world case series of ravulizumab use in patients with myasthenia gravis in romania. Brain Sci. 2025;15(4):350.","journal-title":"Brain Sci"},{"issue":"4","key":"9770_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70158","volume":"32","author":"TH Vu","year":"2025","unstructured":"Vu TH, Mantegazza R, Annane D, Katsuno M, Meisel A, Nicolle MW, et al. Long\u2010term efficacy and safety of ravulizumab in adults with anti\u2010acetylcholine receptor antibody\u2010positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open\u2010label extension. Eur J Neurol. 2025;32(4):e70158.","journal-title":"Eur J Neurol"},{"key":"9770_CR17","unstructured":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension - PubMed [Internet]. [cited 2025 Jun 18]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37103755\/."},{"key":"9770_CR18","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2024 Dec 4]. Available from: https:\/\/training.cochrane.org\/handbook."},{"key":"9770_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"9770_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"9770_CR21","unstructured":"Free Online Spreadsheet Software: Excel | Microsoft 365 [Internet]. [cited 2024 Dec 4]. Available from: https:\/\/www.microsoft.com\/en-us\/microsoft-365\/excel."},{"key":"9770_CR22","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998;841:769\u201372.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"9770_CR23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","volume":"52","author":"GI Wolfe","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487\u20139.","journal-title":"Neurology"},{"issue":"6","key":"9770_CR24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/mus.25198","volume":"54","author":"TM Burns","year":"2016","unstructured":"Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, et al. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. Muscle Nerve. 2016;54(6):1015\u201322.","journal-title":"Muscle Nerve"},{"key":"9770_CR25","unstructured":"ResearchGate [Internet]. [cited 2025 Jun 14]. The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis | Request PDF. Available from: https:\/\/www.researchgate.net\/publication\/261773681_The_Newcastle-Ottawa_Scale_NOS_for_Assessing_the_Quality_of_Non-Randomized_Studies_in_Meta-Analysis."},{"key":"9770_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"10","key":"9770_CR27","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020;18(10):2127\u201333.","journal-title":"JBI Evid Synth"},{"key":"9770_CR28","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration, 2020."},{"key":"9770_CR29","unstructured":"OpenMeta-Analyst: open-source, cross-platform software for advanced meta-analysis | Cochrane Colloquium Abstracts [Internet]. [cited 2025 Jun 18]. Available from: https:\/\/abstracts.cochrane.org\/2010-keystone\/openmeta-analyst-open-source-cross-platform-software-advanced-meta-analysis."},{"issue":"1","key":"9770_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24(1):243.","journal-title":"BMC Med Res Methodol"},{"key":"9770_CR31","unstructured":"16.1.3.2 Imputing standard deviations for changes from baseline [Internet]. [cited 2025 Jun 8]. Available from: https:\/\/handbook-5-1.cochrane.org\/chapter_16\/16_1_3_2_imputing_standard_deviations_for_changes_from_baseline.htm."},{"issue":"3","key":"9770_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"9770_CR33","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses | Cochrane [Internet]. [cited 2025 Jun 18]. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-10."},{"key":"9770_CR34","unstructured":"9.5.3 Strategies for addressing heterogeneity [Internet]. [cited 2024 Aug 13]. Available from: https:\/\/handbook-5-1.cochrane.org\/chapter_9\/9_5_3_strategies_for_addressing_heterogeneity.htm."},{"key":"9770_CR35","unstructured":"10.4.3.1 Recommendations on testing for funnel plot asymmetry [Internet]. [cited 2024 Sep 3]. Available from: https:\/\/handbook-5-1.cochrane.org\/chapter_10\/10_4_3_1_recommendations_on_testing_for_funnel_plot_asymmetry.htm."},{"key":"9770_CR36","unstructured":"Borenstein M, editor. Introduction to meta-analysis. Nachdr. Chichester: Wiley; 2013. 421 p."},{"issue":"5","key":"9770_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100066","volume":"1","author":"T Vu","year":"2022","unstructured":"Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 2022;1(5):EVIDoa2100066.","journal-title":"NEJM Evid"},{"key":"9770_CR38","doi-asserted-by":"publisher","unstructured":"Complement system activation: bridging physiology, pathophysiology, and therapy | Intensive Care Medicine | Springer Nature Link [Internet]. [cited 2026 Jan 29]. Available from: https:\/\/link.springer.com\/article\/https:\/\/doi.org\/10.1007\/s00134-024-07611-4.","DOI":"10.1007\/s00134-024-07611-4."},{"issue":"27","key":"9770_CR39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"9770_CR40","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395\u2013406.","journal-title":"Lancet Neurol"},{"key":"9770_CR41","doi-asserted-by":"publisher","unstructured":"Ravulizumab and Efgartigimod in Myasthenia Gravis | Neurology Neuroimmunology & Neuroinflammation [Internet]. [cited 2025 Jun 18]. Available from: https:\/\/www.neurology.org\/doi\/https:\/\/doi.org\/10.1212\/NXI.0000000000200331.","DOI":"10.1212\/NXI.0000000000200331."}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09770-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09770-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T10:13:53Z","timestamp":1775384033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09770-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9770"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09770-6","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We confirm that this manuscript complies with all instructions to authors, that all authors meet the authorship criteria and have approved the final version of the manuscript, and the PRISMA checklist was used.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"NA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"NA.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"We declare that this study has not been published at all.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous publication"}},{"value":"We declare that we have not used AI in writing any part of this abstract.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI in scientific writing"}}],"article-number":"35"}}